Background: The pharmacokinetic properties of pravastatin, particularly AUC and Cma ~, are variable by population. A description of the pharmacokinetic properties of pravastatin in Mexican mestizos was not found in a search of MEDLINE/ PubMed (key terms: pravastatin, Mexican, and pharmacokinetics; years: 1966-2005). Because Mexicans and Japanese have common ancestors (Mongoloid group), they also have a common gene pool. This gene pool was modified by genetic "bottlenecks" that occurred when these populations migrated to the Americas and when the Mexican population mixed with the Spanish population during the 16th and 17th centuries. Previous studies in Japanese subjects showed 5 main mutations on the hepatic drug transporter OATP-C, resulting in higher Cma x
Results: Twenty-four subjects (15 women, 9 men; mean age, 30.6 years) participated in the study. The mean (SD) Cma x was 9.5 (2.4) ng/mL; Tmax, 0.8 (0.3) hours; AUC0_~, 35.7 (19.7) ng/mL • h; tl/2, 2.7 (1.1) hours; and mean residence time, 3.1 (1.1) hours. One volunteer (4%) had an AUC value that differed substantially from the rest of the study population, producing a bimodal distribution of the pharmacokinetic parameters. No adverse events were observed or reported during the trial.
INTRODUCTION
Pravastatin is a cholesterol-lowering inhibitor of hydroxymethylglutaryl coenzyme A reductase (statin), which is involved in the de novo synthesis of cholesterol. 1,2 The first available statin, mevastatin, was isolated from the fungus Penicillium citrinum but was not marketed due to safety concerns (eg, hepatotoxicity). 3 Pravastatin is indicated for the treatment of hypercholesterolemia and the prevention of cardiovascular disease, diabetes mellitus, 4 and renal disease. 5, 6 Once absorbed, pravastatin undergoes the first-pass effect as it enters the enterohepatic circulation, resulting in poor bioavailability (18%). 7 Pravastatin is metabolized in the stomach and duodenum. 2 A previous study 8 in Japanese subjects showed 5 main mutations on the hepatic drug transporter OATP-C, resulting in higher Cma x and AUC values compared with those in whites. In the Japanese population, the rates of expression of the *lb and "15 alleles have been found to be 46% and 15%, respectively. 8
Because Mexicans and Japanese have common ancestors (Mongoloid group), they also have a common gene pool. This gene pool was modified by genetic "bottlenecks" that occurred when these populations migrated to the Americas and when the Mexican population mixed with the Spanish population during the 16th and 17th centuries. 9 Although the clinical efficacy of pravastatin in Mexican patients has been shown, l° a MEDLINE/PubMed search (key terms: pravastatin, Mexican, and pharmacokinetics; years: 1966-2005) revealed no published pharmacokinetic data for pravastatin in the Mexican population. Therefore, the aim of this study was to evaluate the pharmacokinetic properties of pravastatin in healthy Mexican mestizo volunteers and to compare them with those in white and Japanese populations described in the literature.
SUBJECTS AND METHODS
This open-label, uncontrolled pilot study of the pharmacokinetic properties of pravastatin was conducted at the Division of Pharmacology, Center for Research and Advanced Studies, Mexico City, Mexico. The local ethics committee revised and approved the study protocol. Healthy subjects (as determined by physical examination and laboratory tests [complete blood count, biochemistry, creatinine clearance]) aged 18 to 50 years who could read, understand, and sign an informed-consent form were eligible for the study. Subjects were excluded from the study if they had any known pathology, had ingested any drug in the previous 8 days, used any psychotropic drug, abused drugs or alcohol, or were unwilling to provide written informed consent. Women who were pregnant, possibly pregnant, or breastfeeding were also excluded from the study.
Eligible subjects were recruited from a typical middle-class neighborhood in northern Mexico City. This middle-class group consists mainly of people of mestizo origin (the ancestry of this group is -60% Native American, -38% white, and -2% African 11,12) in Mexico City. 13 A correlation between middle economic income and mestizo origin in Mexico City has been found in a previous work. 13 After an overnight fast, a 10-mg tablet of pravastatin was administered to each subject at 8:00 AM. A light lunch was served 3 hours later. High-performance liquid chromatography (HPLC) was used to determine plasma pravastatin concentrations between 15 minutes and 12 hours after dosing. Blood samples were collected from the cubital vein by a qualified nurse at 0, 15, and 30 minutes and 1, 2, 4, 8, 10, and 12 hours using Vacutainer heparin tubes (Becton, Dickinson and Co., Franklin Lakes, New Jersey). Seven milliliters of whole blood was kept after discarding 3 mL. Plasma was immediately separated by centrifugation (3500g at room temperature for 10 minutes) and kept frozen at -20°C until analysis (within 3 months). Pharmacokinetic properties were compared with data from published studies in white and Japanese populations. Spontaneous reports of adverse events were recorded.
Vital signs (blood pressure, heart rate, and body temperature) were monitored before, during, and at the end of the trial.
Equipment and Reactives
An Agilent series 1100 with automatic degassing system, quaternary pump, heated column, and diode array was used for HPLC. The column was a Zorbax XDB-C18 4.6 x 150 mm (Waters, Milford, Massachusetts). The reagents were Milli-Q deionized water, acetonitrile (Tecsiquim, Mexico City, Mexico), monobasic sodium phosphate (NaHPO4), and dibasic potassium phosphate (K2HPO4) (J.T. Baker, Mexico City, Mexico).
Extraction and Chromatography
Pravastatin was extracted from 1 mL of plasma with C18 extra-clean columns (Alltech, Mexico City, Mexico). Conditioning was carried out with 2 mL of methanol and 1 mL of water. The internal standard was dicloxacillin. Extraction and chromatography were based on the published method of Otter and Mignat. 14 A washing step with 1 mL of water preceded the elution with 0.5 mL of acetonitrile:water 50:50.
The mobile phase was phosphate buffer (20 mmol/L):acetonitrile 56:44 at 1.0 mL/min. The temperature of the column was maintained at 40°C and run time was 8 minutes. The detector was set to 239 nm, and the method was validated according to Causon's procedures. 15 AUC was chosen as the response function. Correlation coefficients were always >0.999; precision was 14.5% at the lower limit of quantification (5 ng/mL) and 12.1% at the higher limit (200 ng/mL). The intraday and interday biases were always <13%.
Pharmacokinetic and Statistical Analysis
Basic pharmacokinetic model-independent parameters were calculated. Quartiles and frequency histograms were used to observe the distribution of Cma x and AUC. Data are given as mean (SD). Best fits were chosen using Akaike criteria 16 provided by the P-Pharm program (Innaphase, Philadelphia, Pennsylvania), which measures the weighted sum of squares considering the number of parameters and number of observations taking the natural logarithm. Statistical comparisons of AUC values were performed using raw data estimations based on SDs and CIs. We compared our data with those from previous studies 8,17-2° using 1-way analysis of variance and the Tukey test. Statistical calculations were performed using Minitab version 14 (Minitab Inc., State College, Pennsylvania).
RESULTS
Twenty-four healthy volunteers (15 women, 9 men; mean age, 30.6 years) participated in the study, and all of them completed it. In the women, mean (SD) age was 33.6 (11.1) years and mean (SD) body weight was 56.0 (24.4) kg; in the men, the mean (SD) age was 29.1 (11.5) years and the mean (SD) body weight was 67.6 (27.8) kg.
Baseline mean (SD) values for the vital signs were as follows: systolic/diastolic blood pressure, 101/65 (33/21) mm Hg; heart rate, 82 (17) bpm; and body temperature, 36.5°C (0.2°C). No significant changes in the mean values were observed after pravastatin administration.
The mean plasma pravastatin concentrations are shown in Figure 1 . Mean (SD) Cm~ ¢ and Tm~ values were 9.5 (2.4) ng/mL and 0.8 (0.3) hours, respectively, giving an AUC0_ ~ of 35.7 (19.7) ng/mL • h (Table I) . One volunteer had an outlier AUC0_ ~ value, producing a bimodal distribution of the pharmacokinetic parameters. The tl/2 of subject 24 was not possible to fit, so the AUC is shown as AUC0_12. The mean Akaike value for individual fittings was 13.3.
The mean tl/2 in the present study (2.7 [ 1.1] hours) was numerically greater than in previous studies (Table II) . 8,17-2° The mean variability of the parameters between patients in this study was 44% (Figure 2 ). The variability in AUC (55%) is explained in part by the subject with the outlying value. No adverse events were reported.
DISCUSSION
Several studies of the pharmacokinetic parameters of pravastatin 10 mg have been published (Table [I with Asian studies. One study 8 in Japanese subjects found 5 common mutations on OATP-C that produce a 5-fold increase in Cm~ x and AUC. The expression rates of the *lb and ~15 alleles in the Japanese population have been found to be 46% and 15%, respectively. 8 In a white population, the expression rate of the ~15 allele was found to be 0%. 8 Our literature search revealed no data for the OATP-C genotype in Mexicans. A previous comparison 9 found the AUC of nifedipine to be more similar between Mexican and Japanese populations than between either of these 2 populations and whites. Ogawa et a118 evaluated the pharmacokinetic properties of pravastatin 10 mg in 84 healthy Japanese volunteers. They found that the Cma x values were 4.8% higher in these subjects compared with the rest of the study population. In the present study, AUC was increased in 4% of subjects, whereas Cma x was not increased in any of the subjects. In a study of 23 healthy Japanese volunteers, Nishizato et al 8 reported 30ATP-C phenotypes (lb, lb/15, and 15/15). In these individuals, the Cma x values were 14, 27, and 49 ng/mL (Table II) . All 3 values were numerically higher than the mean in the present study. Fukazawa et a119 reported a geometric mean Cma x of 13.3 ng/mL (range, 8.2-21.3 ng/mL) and an AUC of 40.0 ng/mL • h (range, 28.1-57.0 ng/mL • h) in Japanese subjects. In the present study, the geometric mean of Cma x was 9.1 ng/mL (range, 4.1-13.7 ng/mL), and the geometric mean of AUC was 31.4 ng/mL-h (range, Ka = absorption rate constant; MRT = mean residence time; CV = coefficient of variation. *This value was an outlier and so has been omitted here.
5.7-93.8 ng/mL • h). Based on these results, it is likely that no mestizo subjects included in the present study expressed the ~lb or "15 OATP-C alleles because these alleles produce phenotypes of Cma ~ of 14 and 49 ng/mL, respectively, and an AUC of 44.2 and 62.1 ng/mL • h, respectively (Table ll) .
On the other hand, Pan et a117 reported a mean Cma ~ of 11.6 ng/mL; tl/2, 2.6 hours; and AUC, 31.3 ng/mL • h after administering pravastatin 10 mg to white patients with hypercholesterolemia. Data from the present study in healthy Mexican mestizo volunteers are similar to those from the study by Pan et al. 17 Because the methods for pharmacokinetic analysis in most published articles use mass spectrometry linked to HPLC, these studies are comparable. 1,2 Furthermore, the pharmacokinetic properties of pravastatin have been shown to be similar between men and women. 2° With pravastatin 10 mg, no accumulation has been reported when the drug is administered BID. The tl/2 of pravastatin 10 mg reported in most studies is between 1.6 and 3.3 hours. 16-2° In the present study, tl/2 fell within that range in 20% of subjects. One subject showed a tl/2 between 4 and 6 hours. The mean tl/2 in the present study was slightly numerically higher compared with those of previous studies, with the exception of the study by Mazzu et al, 21 in which the authors reported a tl/2 of 5.5 hours with pravastatin 40 mg. Pravastatin has "flip-flop" pharmacokinetic properties (ie, absorption is slower than elimination), 7 so the observed tl/2 in all studies mainly represent drug absorption, and in some cases drug distribution, both of which can be influenced by the polymorphism on OATP-C.
We recommend conducting genomic studies on the Mexican population to verify the presence of an OATP-C genotype.
This study is considered a pilot study due to the small sample size and limited statistics compared with previous studies, and because no genomic data were determined. However, it provides an indication of the pharmacokinetic properties in this mestizo population.
CONCLUSIONS
In this small pilot study of the pharmacokinetic properties of pravastatin in healthy Mexican mestizo volunteers, the AUC values were statistically similar to those previously reported in white and Japanese populations. On the other hand, Cma ~ and tl/2 were numerically similar to those in a white population but not to those in some Japanese populations, which was due to the presence of allele ~15 in OATP-C.
